Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis - PubMed (original) (raw)

Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis

Maha R Farhat et al. J Clin Microbiol. 2016 Mar.

Abstract

Molecular diagnostics that rapidly and accurately predict resistance to fluoroquinolone drugs and especially later-generation agents promise to improve treatment outcomes for patients with multidrug-resistant tuberculosis and prevent the spread of disease. Mutations in the gyr genes are known to confer most fluoroquinolone resistance, but knowledge about the effects of gyr mutations on susceptibility to early- versus later-generation fluoroquinolones and about the role of mutation-mutation interactions is limited. Here, we sequenced the full gyrA and gyrB open reading frames in 240 multidrug-resistant and extensively drug-resistant tuberculosis strains and quantified their ofloxacin and moxifloxacin MIC by testing growth at six concentrations for each drug. We constructed a multivariate regression model to assess both the individual mutation effects and interactions on the drug MICs. We found that gyrB mutations contribute to fluoroquinolone resistance both individually and through interactions with gyrA mutations. These effects were statistically significant. In these clinical isolates, several gyrA and gyrB mutations conferred different levels of resistance to ofloxacin and moxifloxacin. Consideration of gyr mutation combinations during the interpretation of molecular test results may improve the accuracy of predicting the fluoroquinolone resistance phenotype. Further, the differential effects of gyr mutations on the activity of early- and later-generation fluoroquinolones requires further investigation and could inform the selection of a fluoroquinolone for treatment.

PubMed Disclaimer

Figures

FIG 1

Estimated ofloxacin (OFX) and moxifloxacin (MXF) MIC distributions in isolates with the gyrA mutation A90V or D94A (there were no isolates with both mutations). MIC distributions are superimposed on a histogram of the observed MICs. The MXF MIC peaks lower than the lower limit of the peak MXF serum concentrations (dotted pink line; 3 mg/liter) (41); however, the OFX MIC peaks higher than the peak serum concentration for OFX (dotted blue line; 2 mg/liter) (42).

FIG 2

Histogram of gyr mutation frequency as a function of MIC by drug. MICs are plotted using a log2 scale. The two extreme MIC bins were collapsed into the adjacent MIC bin. All nonsynonymous mutations were counted except for the lineage gyrA mutations E21Q, T80A, S95T, G247S, and G668D and the gyrB mutations I310M, V340L, and S700T, as the latter 3 were not found to be associated with drug resistance in the multivariate model.

Cited by

Classification of Mycobacterium tuberculosis DR, MDR,XDR Isolates and Identification of Signature MutationPattern of Drug Resistance.
Prasanna A, Niranjan V. Prasanna A, et al. Bioinformation. 2019 Apr 15;15(4):261-268. doi: 10.6026/97320630015261. eCollection 2019. Bioinformation. 2019. PMID: 31285643 Free PMC article.
GWAS for quantitative resistance phenotypes in Mycobacterium tuberculosis reveals resistance genes and regulatory regions.
Farhat MR, Freschi L, Calderon R, Ioerger T, Snyder M, Meehan CJ, de Jong B, Rigouts L, Sloutsky A, Kaur D, Sunyaev S, van Soolingen D, Shendure J, Sacchettini J, Murray M. Farhat MR, et al. Nat Commun. 2019 May 13;10(1):2128. doi: 10.1038/s41467-019-10110-6. Nat Commun. 2019. PMID: 31086182 Free PMC article.
Cryptic Microheteroresistance Explains Mycobacterium tuberculosis Phenotypic Resistance.
Metcalfe JZ, Streicher E, Theron G, Colman RE, Allender C, Lemmer D, Warren R, Engelthaler DM. Metcalfe JZ, et al. Am J Respir Crit Care Med. 2017 Nov 1;196(9):1191-1201. doi: 10.1164/rccm.201703-0556OC. Am J Respir Crit Care Med. 2017. PMID: 28614668 Free PMC article.
Limited Effect of Later-Generation Fluoroquinolones in the Treatment of Ofloxacin-Resistant and Moxifloxacin-Susceptible Multidrug-Resistant Tuberculosis.
Lee H, Ahn S, Hwang NY, Jeon K, Kwon OJ, Huh HJ, Lee NY, Kim CK, Koh WJ. Lee H, et al. Antimicrob Agents Chemother. 2018 Jan 25;62(2):e01784-17. doi: 10.1128/AAC.01784-17. Print 2018 Feb. Antimicrob Agents Chemother. 2018. PMID: 29203478 Free PMC article.
Xpert MTB/XDR: a 10-Color Reflex Assay Suitable for Point-of-Care Settings To Detect Isoniazid, Fluoroquinolone, and Second-Line-Injectable-Drug Resistance Directly from Mycobacterium tuberculosis-Positive Sputum.
Cao Y, Parmar H, Gaur RL, Lieu D, Raghunath S, Via N, Battaglia S, Cirillo DM, Denkinger C, Georghiou S, Kwiatkowski R, Persing D, Alland D, Chakravorty S. Cao Y, et al. J Clin Microbiol. 2021 Feb 18;59(3):e02314-20. doi: 10.1128/JCM.02314-20. Print 2021 Feb 18. J Clin Microbiol. 2021. PMID: 33298611 Free PMC article.

References

1. Mitnick CD, Franke MF, Rich ML, Alcantara Viru FA, Appleton SC, Atwood SS, Bayona JN, Bonilla CA, Chalco K, Fraser HSF, Furin JJ, Guerra D, Hurtado RM, Joseph K, Llaro K, Mestanza L, Mukherjee JS, Muñoz M, Palacios E, Sanchez E, Seung KJ, Shin SS, Sloutsky A, Tolman AW, Becerra MC. 2013. Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality. PLoS One 8:e58664. doi:10.1371/journal.pone.0058664. - DOI - PMC - PubMed
1. Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F. 2007. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs 67:2077–2099. doi:10.2165/00003495-200767140-00007. - DOI - PubMed
1. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. 2010. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 51:6–14. doi:10.1086/653115. - DOI - PMC - PubMed
1. Farhat MR, Mitnick CD, Franke MF, Kaur D, Sloutsky A, Murray M, Jacobson KR. 2015. Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment. Int J Tuberc Lung Dis 19:339–341. doi:10.5588/ijtld.14.0814. - DOI - PMC - PubMed
1. World Health Organization. 2014. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization, Geneva, Switzerland. - PubMed

Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis - PubMed (original) (raw)